Inhibikase Therapeutics Announces Orphan Drug Designation For Risvodetinib

(RTTNews) - Inhibikase Therapeutics, Inc. (IKT) announced that risvodetinib has been granted Orphan Drug Designation by the FDA for the treatment of Multiple System Atrophy. MSA is an aggressive form of Parkinsonism.

"As we look ahead, we are advancing our ongoing animal model studies of risvodetinib to determine its therapeutic potential to block progression and correct functional loss in MSA. These studies will form the basis of our planned Phase 2 clinical study and we look forward to providing further updates on the potential timing of the Phase 2 trial in the coming quarters," said Milton Werner, Chief Executive of Inhibikase Therapeutics.

For More Such Health News, visit rttnews.com.